Shay Capital’s Jade Biosciences JBIO Stock Holding History

Shay Capital’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-703	Closed	-$727K	–	286
2024 Q1	$727K	Buy	+703	New	+$537K	0.11%	145

Other funds holding JBIO

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Shay Capital's JBIO Position: Q2 2024 in Review

Shay Capital sold out of Jade Biosciences (JBIO) in Q2 2024, closing a stake of 703 shares — an estimated $727K sold.

Shay Capital first reported a position in JBIO in Q1 2024 and held it in 1 quarter. The position peaked at $727K in Q1 2024. 80 funds tracked by Wall St. Rank hold JBIO as of Q2 2024.

Shay Capital reported no remaining Jade Biosciences position as of Q2 2024 after selling out during the quarter.
Shay Capital sold 703 Jade Biosciences shares in Q2 2024, an estimated $727K.
Shay Capital first reported a position in Jade Biosciences in Q1 2024 and held it in 1 quarter.
Shay Capital's Jade Biosciences position peaked at $727K in Q1 2024.
80 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2024.

Based on Shay Capital's 13F filing for Q2 2024, filed 14 Aug 2024.